14.07.2023 • News

ExxonMobil Acquires Denbury Valued at €4.5 Billion

ExxonMobil has acquired Denbury, a carbon capture, utilization, and storage (CCUS) and enhanced oil recovery company. The all-stock transaction is valued at €4.5 billion.

The acquisition provides ExxonMobil with the largest owned and operated CO2 pipeline network in the US, with over 2000 km of pipeline and 10 onshore sequestration sites. This will contribute to multiple low-carbon value chains including CCUS and hydrogen, ammonia, and biofuel production.

“The breadth of Denbury’s network, when added to ExxonMobil’s decades of experience and capabilities in CCUS, gives us the opportunity to play an even greater role in a thoughtful energy transition, as we continue to deliver on our commitment to provide the world with the vital energy and products it needs," said Darren Woods, Chairman and CEO of ExxonMobil. 

Chris Kendall, Denbury’s President and Chief Executive Officer commented, “This transaction is a compelling opportunity for Denbury to join an admired global energy leader with a low-carbon focus, a robust balance sheet and a leading shareholder return program."

The acquisition also includes Denbury's Gulf Coast and Rocky Mountain oil and natural gas operations, with reserves of over 200 million barrels of oil and 47,000 oil-equivalent barrels per day production. The transaction is expected to close in Q4 2023. 

ExxonMobils €4.5 billion purchase of Denbury boosts low carbon solutions...
ExxonMobil's €4.5 billion purchase of Denbury boosts low carbon solutions division. © Askar - stock.adobe.com

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read